NSCLC(7)1. N Engl J Med (IF: 74.699; Q1) 2020 Nov19.DOI: 10.1056/NEJMoa2027187First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer劳拉替尼或克唑替尼一线治疗 ALK 阳性晚期肺癌2. J Thorac Oncol (IF: 13.357; Q1) 2020 Nov 6.DOI: 10.1016/j.jtho.2020.10.001Brief Report: Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination with Pegilodecakin in Patients with Metastatic Non-Small-Cell Lung Cancer (CYPRESS-1 and CYPRESS-2)免疫检查点单药或联合Pegilodecakin 用于治疗转移性非小细胞肺癌患者的随机 2 期临床试验(CEPRESS-1 和CEPRESS-2)3. J Thorac Oncol (IF: 13.357; Q1) 2020 Nov25.DOI: 10.1016/j.jtho.2020.11.004Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial布格替尼用于既往接受过阿来替尼或其他酪氨酸激酶抑制剂的 ALK 阳性非小细胞肺癌日本患者:2 期J-ALTA 研究结果4. J Thorac Oncol (IF: 13.357; Q1) 2020 Nov 6.DOI: 10.1016/j.jtho.2020.09.022Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials阿替利珠单抗与多西他赛在经治非小细胞肺癌患者中的比较:II 期 POPLAR 和 III 期OAK 临床试验的最终结果5. Lancet Respir Med (IF: 25.094; Q1) 2020 Oct20.DOI: 10.1016/S2213-2600(20)30391-XPembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials帕博利珠单抗联合或不联合放疗治疗转移性非小细胞肺癌:两项随机试验的合并分析6. J Thorac Oncol (IF: 13.357; Q1) 2020 Nov12.DOI: 10.1016/j.jtho.2020.10.129Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14).在局部晚期 IIIA/B 期非小细胞肺癌患者中,同步接受纳武利尤单抗和标准同步放化疗的无进展生存和总生存期:欧洲胸部肿瘤平台 NICOLAS II 期临床试验结果(ETOP 6-14)7. Clin Cancer Res(IF: 10.107; Q1) 2020 Nov 10.DOI:10.1158/1078-0432.CCR-20-2861MET exon 14-altered lung cancers and MET inhibitor resistanceMET 外显子 14 改变的肺癌与 MET 抑制剂耐药性肺部神经内分泌肿瘤(1)8. J Clin Oncol (IF: 32.956;Q1 ) 2020 Nov 2.DOI:10.1200/JCO.20.01806Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206伊立替康联合顺铂与依托泊苷联合顺铂治疗完全切除的高级别肺神经内分泌癌的随机III 期研究:JCOG1205/1206SCLC(2)9. Br J Cancer(IF: 23.237; Q1) 2020 Nov 16.DOI:10.1038/s41416-020-01055-5A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer一项比较贝洛替康与拓扑替康单药治疗敏感复发小细胞肺癌的疗效和安全性的 2b 期随机研究10. J ThoracOncol (IF: 13.357; Q1) 2020 Nov 6.DOI: 10.1016/j.jtho.2020.10.002Camrelizumab Plus Apatinib in Extensive-Stage Small-Cell Lung Cancer (PASSION): A Multicenter, Two-Stage, Phase 2 Trial卡瑞利珠单抗联合阿帕替尼治疗广泛期小细胞肺癌(PASSION):一项多中心、两阶段、2期临床试验
二、meta分析/综述(2)
11. CA Cancer JClin (IF: 292.278; Q1) 2020 Nov 9. DOI: 10.1016/10.3322/caac.21650Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions晚期实体瘤循环肿瘤 DNA:临床意义和未来研究方向12. Cell Mol Immunol (IF: 8.484; Q1) 2020 Nov 11.DOI: 10.1038/s41423-020-00577-5The cutting-edge progress of immune-checkpoint blockade in lung cancer肺癌中免疫检查点抑制剂的最新进展
三、 基础研究/letters/评述(5)
13. J Thorac Oncol (IF: 13.357; Q1) 2020 Nov 6.DOI: 10.1016/j.jtho.2020.09.023Novel resistance mechanisms including L1196Q, P1094H, and R1248_D1249 insertion in three patients with non-small-cell lung cancer following ALK tyrosine kinase inhibitor treatment在 ALK 酪氨酸激酶抑制剂治疗后 3 例非小细胞肺癌患者新的耐药机制,包括 L1196Q、P1094H 和R1248_D1249 插入14. Clin Cancer Res(IF: 10.107; Q1) 2020 Nov 17.DOI: 0.1158/1078-0432.CCR-20-2845AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small Cell Lung CancerAMG757,一种长半衰期、DLL3 靶向的双特异性 T 细胞激活剂,在小细胞肺癌的临床前模型中显示出高效力和高敏感性15. Clin Cancer Res(IF: 10.107; Q1) 2020 Nov 13.DOI:10.1158/1078-0432.CCR-20-3507Senescent T-cells as a resistance mechanism to lung cancer immunotherapy肺癌免疫治疗耐药机制:衰老 T 细胞16. J Thorac Oncol (IF: 13.357; Q1) 2020 Nov 25.DOI: 10.1016/j.jtho.2020.11.006YAP1 Expression in Small Cell Lung Cancer Defines a Distinct Subtype with T-cell Inflamed PhenotypeYAP1 表达在小细胞肺癌中定义了一个独特亚型:T 细胞炎症表型17. Ann Oncol(IF: 18.274; Q1) 2020 Nov 22.DOI: 10.1016/j.annonc.2020.11.010Expanding the nanotherapeutic toolbox for non-small-cell lung cancer非小细胞肺癌纳米治疗工具的拓展